LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

Home・Aktien・Omeros Corp

Omeros Corp

Geschlossen

Branche Gesundheitswesen

4.05 0.75

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.98

Max

4.16

Schlüsselkennzahlen
By Trading Economics
Einkommen	-56M
EPS	-0.15

Dividenden
By Dow Jones
Nächstes Ergebnis	7. Nov. 2024

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-9.5M 216M
Vorheriger Eröffnungskurs	3.3
Vorheriger Schlusskurs	4.05

Nachrichtenstimmung

By Acuity

58%

42%

315 / 389 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

4.05 / 4.21 Unterstützung & Widerstand

Omeros Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

1. Nov. 2024, 22:50 UTC

Heiße Aktien

Stocks to Watch: Nvidia, Intel, Sherwin-Williams, Dow, Nuwellis

1. Nov. 2024, 22:43 UTC

Wichtige Markttreiber

Nvidia, Sherwin-Williams Shares Up on Addition to DJIA

1. Nov. 2024, 22:13 UTC

Wichtige Markttreiber

Chewy Up 5% on S&P MidCap 400 Inclusion

1. Nov. 2024, 21:39 UTC

Ergebnisse

Insurance Company Chubb Projects Up to $300 Million Pre-Tax Loss on Hurricane

1. Nov. 2024, 22:51 UTC

Ergebnisse

Correction to Nvidia to Replace Intel in Dow Jones Industrial Average Article -- WSJ

1. Nov. 2024, 22:00 UTC

Top News

Ergebnisse

Nvidia to Replace Intel in Dow Jones Industrial Average. Sherwin-Williams Also Joins. -- WSJ

1. Nov. 2024, 21:29 UTC

Top News

Ergebnisse

Exxon and Chevron Feel Brunt of Cheaper Oil -- 2nd Update

1. Nov. 2024, 21:24 UTC

Ergebnisse

Insurance Company Chubb Projects Up to $300M Pre-Tax Loss on Hurricane

1. Nov. 2024, 20:57 UTC

Ergebnisse

BYD's Sales Hit a Record. It's Neck and Neck in EV Race With Tesla. -- Barrons.com

1. Nov. 2024, 20:50 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

1. Nov. 2024, 20:50 UTC

Market Talk

Ergebnisse

Auto & Transport Roundup: Market Talk

1. Nov. 2024, 20:48 UTC

Top News

Ergebnisse

Stocks Wrap Up Volatile Week With Gains -- WSJ

1. Nov. 2024, 20:44 UTC

Ergebnisse

AI Spending Dominated Big Tech Earnings. Why These 2 Stocks Got a Pass From Investors. -- Barrons.com

1. Nov. 2024, 20:10 UTC

Top News

Nasdaq, Dow Rebound After Jobs Report Disappoints -- WSJ

1. Nov. 2024, 19:47 UTC

Ergebnisse

Apple's Earnings Confirmed 1 Thing: Nobody Knows When a Major Upgrade Cycle Is Coming -- Barrons.com

1. Nov. 2024, 19:43 UTC

Market Talk

U.S. Natural Gas Ends Week Lower Awaiting Winter Weather -- Market Talk

1. Nov. 2024, 19:32 UTC

Market Talk

Oil Futures End Week With Losses -- Market Talk

1. Nov. 2024, 19:14 UTC

Top News

U.S. Job Growth Gradually Slowing Beyond Storm, Strike Disruptions - Analysis

1. Nov. 2024, 18:41 UTC

Market Talk

Mexican Manufacturing PMIs Point to Sluggish October -- Market Talk

1. Nov. 2024, 18:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. Nov. 2024, 18:35 UTC

Market Talk

November Fed Meeting Seen as Routine -- Market Talk

1. Nov. 2024, 18:33 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Apple, Amazon, Intel, Boeing, Super Micro, Exxon, and More -- Barrons.com

1. Nov. 2024, 18:31 UTC

Market Talk

SPDR Gold Falls Late in Trading -- Market Talk

1. Nov. 2024, 18:06 UTC

Ergebnisse

Amazon's Big Spending Is Getting a Pass From Investors. Here's Why. -- Barrons.com

1. Nov. 2024, 18:02 UTC

Top News

U.S. Added Just 12,000 Jobs in October; Dow, Nasdaq Rally After Selloff -- WSJ

1. Nov. 2024, 17:46 UTC

Market Talk

Ergebnisse

Uber on Right Path to Achieve Mid-Term Targets -- Market Talk

1. Nov. 2024, 17:45 UTC

Top News

U.S. Added 12,000 Jobs in October as Storms Sidelined Workers -- 6th Update

1. Nov. 2024, 17:44 UTC

Market Talk

Global Equities Roundup: Market Talk

1. Nov. 2024, 17:44 UTC

Market Talk

McDonald's Can Recover From Short-Term Struggles, Analysts Say -- Market Talk

1. Nov. 2024, 17:33 UTC

Market Talk

Abbott's Baby-Formula Lawsuit Win Could Decrease Liabilities -- Market Talk

Peer-Vergleich

Kursveränderung

Omeros Corp Prognose

Rating-Konsens

By TipRanks

Neutral

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Omeros Corp – Dist abgegeben haben.

Technischer Score

By Trading Central

4.05 / 4.21Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Stimmung

By Acuity

315 / 389 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Omeros Corp

Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. Its lead drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens replacement for adult and pediatric patients. Its drug candidate narsoplimab is the subject of a biologics license application (BLA) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). It also has multiple Phase III and Phase II clinical-stage development programs in its pipeline, which are focused on complement-mediated disorders, including immunoglobulin A (IgA) nephropathy, atypical hemolytic uremic syndrome (aHUS) and COVID-19.